NGAL ELISA Kit (human)

H-KIT 036

Overview

NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a sensitive and early biomarker for renal tubular injury, especially useful in diagnosing Acute Kidney Injury (AKI). NGAL levels rise 2–3 days before creatinine, enabling earlier clinical intervention.

 Clinical Significance

Traditionally, AKI diagnosis relies on:

• Serum creatinine changes
• Urine output metrics

However, these markers are delayed, non-specific, and influenced by external factors (e.g., nutrition, muscle mass).

NGAL offers:

• Rapid detection following kidney injury
• Early risk stratification
• Informed clinical decisions regarding fluid management and nephrotoxic drug exposure

NGAL ELISA Kits Features

• Species-Specific Kits: Human, Mouse, Rat, Pig, Dog, Monkey
• Pre-coated 96-well ELISA plates
• Ready-to-use reagents including working solutions and calibrators
• High reproducibility & sensitivity

 Kit Components

• Pre-coated ELISA plate (96 wells)
• Calibrators (ready-to-use)
• Detection antibody
• Substrate solution
• Stop solution
• Wash buffer
• Detailed protocol

 Applications

• Preclinical and clinical AKI studies
• Nephrotoxicity testing
• Drug safety trials
• Biomarker discovery
• Kidney disease research

 Regulatory Insight

• NGAL use in Phase I clinical trials is supported by:
• • FDA (U.S. Food and Drug Administration)
  • EMA (European Medicines Agency)

Ordering Information

About NGAL

• Gene Symbol: LCN2
• Expression: Renal tubular epithelial cells
• Biological Role: Involved in innate immunity and iron transport
• Clinical Role: Early biomarker for AKI, useful in emergency, ICU, nephrology, and preclinical studies